^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Colorectal Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor) +
    spartalizumab (PDR001) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

    Excerpt:
    ...- Participants must have histologically or cytologically confirmed metastatic colorectal cancer and a documented BRAF V600E mutation by a CLIA-certified laboratory test and must be wild-type for KRAS and NRAS....
    Trial ID:
    NCT03668431
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Nat Med
    Title:

    Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

    Published date:
    01/26/2023
    Excerpt:
    We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAFV600E CRC....The study met its primary end point with a confirmed response rate (24.3% in all patients; 25% in microsatellite stable patients) and durability that were favorable relative to historical controls of BRAF-targeted combinations alone.
    DOI:
    10.1038/s41591-022-02181-8
    Trial ID:
    NCT03668431
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-GI 2020
    Title:

    SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

    Published date:
    07/01/2020
    Excerpt:
    Spartalizumab, dabrafenib, and trametinib was well-tolerated and produced favorable response rates and durability relative to historical controls in BRAFV600E CRC patients.
    DOI:
    https://doi.org/10.1016/j.annonc.2020.04.041